Evidence that thalidomide modifies the immune response of patients suffering from actinic prurigo

International Journal of Dermatology

Volumn 43, Issue 12, 2004, Pages 893-897

  Estrada G , Iris ^a   Garibay Escobar, Adriana ^a   Núñez Vázquez, Angela ^a   Hojyo Tomoka, Teresa ^a   Vega Memije, Elisa ^a   Cortés Franco, Roberto ^a   Pérez Uribe, Adriana ^a   Flores Romo, Leopoldo ^a   Santos Argumedo, Leopoldo ^a   Estrada Parra, Sergio ^a   Domínguez Soto, Luciano ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 4; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ACTINIC KERATOSIS; ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE MARKER; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED MEDICINE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE COUNT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRURIGO; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIGENS, CD3; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-4; MEXICO; MIDDLE AGED; PHOTOSENSITIVITY DISORDERS; PROSPECTIVE STUDIES; PRURIGO; REMISSION INDUCTION; T-LYMPHOCYTES; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 10444283480     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2004.02274.x     Document Type: Article

References (25)

1. Hojyo-Tomoka Vega-Memije E, Granados J, Flores O, et al. Actnic prurigo: an update. Int J Dermatol 1995; 34: 380-384.
2. Hojyo-Tomoka MT, Vega-Memije ME, Cortés-Franco R, et al. Diagnosis and treatment of actinic prurigo. Dermatol Ther 2003; 16: 40-44.
3. Moncada B, González-Amaro R, Baranda L, et al. Immunopathology of polymorphous light eruption. J Am Acad Dermatol 1984; 10: 970-973.
4. Bernal JE, Durán de Rueda MM, Ordóñez CP, et al. Actinic prurigo among the Chimila Indians in Colombia. J Am Acad Dermatol 1990; 22: 1049-1051.
5. Sheridan DP, Lane PR, Irvine JE, et al. HLA typing in actinic prurigo. J Am Acad Dermatol 1990; 22: 1019-1023.
6. 4 may determine expression of actinic prurigo. J Am Acad Dermatol 1997; 36: 935-937.
7. 4 in the genetic susceptibility to actinic prurigo. J Am Acad Dermatol 1997; 36: 935-937.
8. 4/DRB1* 0407. Br J Dermatol 1999; 140 232-236.
9. Londoño F. Thalidomide in the treatment of actinic prurigo. Int J Dermatol 1973; 12: 326-328.
10. Saúl A, Flores O, Novales J. Polymorphous light eruption: treatment with thalidomide. Australas J Dermatol 1976; 17: 17-21.
11. Vega ME, Hojyo-Tomoka MT, Dominguez-Soto L. Tratamiento del prúrigo actínico con talidomida. estudio de 3 0 pacientes. Dermatol Rev Mex 1993; 37: 342-343.
12. Arrese JE, Domínguez-Soto L, Hojyo-Tomoka MT, et al. J Am Acad Dermartol 2001; 44: 957-961.
13. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
14. Haslett PAJ, Corral LG, Albert M, et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187: 1885-1892.
15. Verbon A, Juffermans NP, Speelman P et al. Antimicrob Agents Chemother 2000; 44: 2286-2290.
16. Oliver SJ, Jikuchi T, Krueger JG, et al. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol 2002; 102: 215-236.
17. Bekker LG, Haslett P, Maartens G, et al. Thalidomide-induced antigen-specific immune stimulation in patients with Human Immunodeficiency Virus type 1 and Tuberculosis. J Infect Dis 2000; 181: 954-965.
18. Partida-Sánchez S, Favila-Castillo L, Pedraza-Sánchez S, et al. IgG antibody subclasses, tumor necrosis factor and interferon gamma levels in patients with type II lepra reaction on thalidomide treatment. Int Arch Aller Immunol 1998; 173: 1730-1735.
19. Marriot JB, Muller G, Dalgleish AG. Thalidomide as an emerging immunotherapeutic agent. Immunol Today 1999; 20: 538-540.
20. Dredge K, Marriot JB, Todryk SM, et al. J Immunol 2002; 168: 4914-4919.
21. Mchugh SM, Rifkin IR, Deighton J, et al. Clin Exp Immunol 1995; 99: 160-167.
22. Moller DR, Wysocka M, Greenlee BM, et al. 1997; 159 5157-5161.
23. Gad SM, Shanon EJ, Krotosi WA, et al. Thalidomide induces imbalance in T-lymphocyte subpopulations in the circulating blood of healthy mates. Lepr Rev 1985; 56: 35-39.
24. Umaña A, Gomez A, Durán MM, et al. Lymphocyte subtypes and adhesion molecules in actinic prurigo: observations with cyclosporin A. Int J Dermatol 2002; 41: 139-145.
25. Yong-Gee SA, Muir JB. Long-term thalidomide for actinic prurigo. Australas J Dermatol 2001; 42: 281-283.